ArticleScientific reports2025
Immunological characterization of hepatitis B core antigen antibody among vaccinated adults lacking hepatitis B surface antigen in ethiopia: A multicenter facility-based study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) infection remains a major public health challenge in Ethiopia, particularly among high-risk adult populations such as health professionals. Despite vaccination efforts, the prevalence and determinants of anti-hepatitis B core antibody (anti-HBc) seroreactivity among vaccinated adult health professionals lacking hepatitis B surface antigen (HBsAg) are not well characterized. Objective This study aimed to determine the prevalence and predictors of anti-HBc seroreactivity among HBsAg-negative vaccinated adult health professionals in hospitals of the northwestern region of Ethiopia. A facility-based cross-sectional study was conducted among 399 adult health professional who completed HBV vaccination series and were HBsAg negative from April to September 2024. Data on sociodemographic, clinical, and vaccine-related characteristics were collected via questionnaire. Serum samples were tested for HBsAg and anti-HBc using enzyme-linked immunosorbent assay (ELISA) kits at Debre Markos Blood Bank Laboratory. Data were analyzed using SPSS version 25. Bivariate and multivariate logistic regression analyses were performed to identify significant predictors of anti-HBc seroreactivity. In this study, the overall anti-HBc seroreactivity among HBsAg-negative vaccinated adult healthcare professionals was 25/399 (6.3%, 95% CI: 4.0%-9.0%). Participants born in rural areas had an anti-HBc seropositivity rate of 8.1%. Additionally, midwives exhibited a seropositivity rate of 11.7%. Among participants who had undergone organ transplantation, 66.7% showed anti-HBc seroreactivity. Moreover, among participants with a family history of liver disease, the prevalence of anti-HBc was 30.0%. Moreover, a previous history of chronic kidney disease (AOR: 9.1, 95% CI: 7.56–11.98, P < 0.014) and obesity (AOR: 6.9, 95% CI: 4.91–8.63, P < 0.003) were significant predictors of anti-HBc seroreactivity. Anti-HBc seroprevalence among HBsAg-negative vaccinated adult healthcare professionals was notable. This finding underscores the critical need for post-vaccination testing to identify HBV infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.